Bionano Genomics Inc(BNGO) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 18 at 7:56 PM ET (Korea 9/19 08:56)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -3.73 | Insider Own | 5.93% | Shs Outstand | 11.8M | Perf Week | 41.8% |
| Market Cap | 0.02B | Forward P/E | - | EPS next Y | 54.67% | Insider Trans | 1.16% | Shs Float | 11.1M | Perf Month | 40.65% |
| Enterprise Value | 0.02B | PEG | - | EPS next Q | -0.45 | Inst Own | 10.35% | Short Float | 11.04% | Perf Quarter | 51.75% |
| Income | -0.03B | P/S | 0.68 | EPS this Y | 67.1% | Inst Trans | -1.36% | Short Ratio | 1.46 | Perf Half Y | 54.46% |
| Sales | 0.03B | P/B | 0.64 | EPS next 5Y | 56.92% | ROA | -52.04% | Short Interest | 1.22M | Perf YTD | 13.07% |
| Book/sh | 2.68 | P/C | 1.96 | EPS past 3/5Y | 73.98% 54.05% | ROE | -83.56% | 52W High | -22.42% ($2.23) | Perf Year | -3.35% |
| Cash/sh | 0.88 | P/FCF | - | Sales past 3/5Y | 0.84% 27.37% | ROIC | -85.92% | 52W Low | 73% ($1.00) | Perf 3Y | -99.04% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 91.68% | Gross Margin | 47.5% | Volatility(W/M) | 27.04% 10.24% | Perf 5Y | -99.95% |
| Dividend TTM | - | EV/Sales | 0.55 | Sales Y/Y TTM | 10.03% | Oper. Margin | -106.67% | ATR (14) | 0.15 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.96 | EPS Q/Q | 67.74% | Profit Margin | -106.58% | RSI (14) | 79.41 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.48 | Sales Q/Q | 21.36% | SMA20 | 32.67% ($1.3) | Beta | 1.63 | Target Price | $4 |
| Payout | - | Debt/Eq | 0.21 | Earnings | 2026/8/10 | SMA50 | 43.28% ($1.21) | Rel Volume | 1.43 | Prev Close | $1.74 |
| Employees | 97 | LT Debt/Eq | 0.18 | EPS/Sales Surpr. | 1.49% 8.2% | SMA200 | 36.4% ($1.27) | Avg Volume(3M) | 0.84M | Price | $1.73 |
| IPO | 2018/9/21 | Option/Short | No/Yes | Trades | 3622 | Volume | 1,197,986 | Change | -0.57% |
Company
BNGO is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧬 Bionano Genomics () is a US genomics analysis company that develops and sells the 'Saphyr' Optical Genome Mapping (OGM) system, which analyzes large-scale structural variations in DNA at high resolution. It supplies instruments and reagents to the research and clinical diagnostics fields, and is a small-cap healthcare name that has recently been trimming its cost structure and sharpening its focus on high-margin, recurring-revenue customers to improve profitability.
Over the past 1 year, roughly in the middle
22% below its 1-year high.
BNGO has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +67.1% this year.
Tap to view numbers
The stock looks undervalued
Trading at - times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 3 quarters.
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -99.0% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership is about average
Institutions hold 10.3%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
VXF 0.00%It ranks #4 in the industry
Based on market cap of $20M.
BNGO $20M PER -
ISRG $139B PER 45.1
BDX $49B PER 54.6
MDLN $42B PER 37.1
FAQ
What kind of company is BNGO?
BNGO belongs to the Healthcare sector and operates in the Medical Instruments & Supplies industry.
What is the market cap of BNGO?
The market cap of BNGO is approximately $20M, ranking 5,281 within its sector.
What is the 52-week high and low for BNGO?
BNGO has recorded a 52-week high of $2.23 and a low of $1.00.
